Phase I and Pharmacokinetic Study of Mitomycin C and Celecoxib as Potential Modulators of Tumor Resistance to Irinotecan in Patients With Solid Malignancies
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-008-0826-3
Full Text
Open PDFAbstract
Available in full text
Date
September 16, 2008
Authors
Publisher
Springer Science and Business Media LLC